Clinical Trial Update: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation and expansion study of VRx-3996 with valganciclovir in Epstein-Barr virus-associated lymphoma and other EBV-related lymphoproliferativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Associated Lymphoma
• Lymphoproliferative Disorders

Drugs mentioned

• VRx-3996
• Valganciclovir (Valganciclovir)

Snippet

Sponsor: Viracta Therapeutics, Inc. | Conditions: Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-03-20